Beam Financial Statements From 2010 to 2024

Stocks . USA . 
Stock . Beam Therapeutics
BEAM Stock  USD 23.58  0.91  3.72%   
Beam Therapeutics financial statements provide useful quarterly and yearly information to potential Beam Therapeutics investors about the company's current and past financial position, as well as its overall management performance and changes in financial position over time. Historical trend examination of various income statement and balance sheet accounts found on Beam Therapeutics financial statements helps investors assess Beam Therapeutics' valuation, profitability, and current liquidity needs. Key fundamental drivers impacting Beam Therapeutics' valuation are summarized below:
Gross Profit
-250.7 M
Profit Margin
(0.41)
Market Capitalization
2 B
Enterprise Value Revenue
3.6157
Revenue
349.6 M
There are over one hundred nineteen available fundamental signals for Beam Therapeutics, which can be analyzed over time and compared to other ratios. Self-guided Investors are advised to validate Beam Therapeutics' prevailing fundamentals against the trend between 2010 and 2024 to make sure the company can sustain itself down the road. As of the 22nd of November 2024, Market Cap is likely to grow to about 3.8 B. Also, Enterprise Value is likely to grow to about 3.5 B

Beam Therapeutics Total Revenue

396.59 Million

Check Beam Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Beam Therapeutics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 11.7 M, Interest Expense of 49 M or Selling General Administrative of 122.7 M, as well as many indicators such as Price To Sales Ratio of 5.28, Dividend Yield of 0.0106 or PTB Ratio of 2.25. Beam financial statements analysis is a perfect complement when working with Beam Therapeutics Valuation or Volatility modules.
  
Check out the analysis of Beam Therapeutics Correlation against competitors.
To learn how to invest in Beam Stock, please use our How to Invest in Beam Therapeutics guide.

Beam Therapeutics Balance Sheet

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Total Assets794.1 M1.5 B390.9 M
Slightly volatile
Short and Long Term Debt Total113.9 M173.2 M51.2 M
Slightly volatile
Other Current Liabilities67.4 M122.5 M35.8 M
Slightly volatile
Total Current Liabilities126.7 M205.6 M65.3 M
Slightly volatile
Property Plant And Equipment Net132.8 M237.8 M65.3 M
Slightly volatile
Accounts Payable1.5 M1.6 M3.1 M
Slightly volatile
Cash311.5 M435.9 M153.8 M
Slightly volatile
Non Current Assets Total193.3 M248.7 M95.1 M
Slightly volatile
Non Currrent Assets Other10.3 M10.9 M22.7 M
Pretty Stable
Cash And Short Term Investments1.2 B1.2 B335.7 M
Slightly volatile
Common Stock Shares Outstanding56.2 M77.2 M33.6 M
Slightly volatile
Liabilities And Stockholders Equity794.1 M1.5 B390.9 M
Slightly volatile
Non Current Liabilities Total193.1 M272.8 M94.8 M
Slightly volatile
Other Current Assets22.2 M21.2 M5.9 M
Slightly volatile
Other Stockholder Equity2.3 B2.2 B565.8 M
Slightly volatile
Total Liabilities319.8 M478.4 M160.1 M
Slightly volatile
Total Current Assets1.3 B1.2 B340.6 M
Slightly volatile
Short Term Debt8.2 M13.3 M4.3 M
Slightly volatile
Common Stock458.7 K816 K227.5 K
Slightly volatile
Other Liabilities259.5 M247.1 M72.5 M
Slightly volatile
Other Assets14.8 M16.9 M7.6 M
Slightly volatile
Capital Stock775.2 K816 K171.3 M
Slightly volatile
Non Current Liabilities Other2.9 M3 M3.9 M
Slightly volatile
Net Working Capital610.2 M1 B328 M
Slightly volatile
Property Plant Equipment282.7 M269.3 M86.3 M
Slightly volatile
Long Term Debt3.4 M2.7 M4.1 M
Slightly volatile
Short Term Investments483.4 M754 M211.5 M
Slightly volatile
Capital Lease Obligations136.4 M172.7 M65.7 M
Slightly volatile
Deferred Long Term Liabilities2.5 M2.8 M3 M
Slightly volatile
Property Plant And Equipment Gross206.1 M288 M104.7 M
Slightly volatile
Short and Long Term Debt2.1 M2.6 M1.6 M
Slightly volatile
Common Stock Total Equity547.2 K615.6 K670.3 K
Slightly volatile
Capital Surpluse1.3 B1.4 B1.6 B
Slightly volatile

Beam Therapeutics Income Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Depreciation And Amortization11.7 M20 M5.8 M
Slightly volatile
Selling General Administrative122.7 M116.8 M30.8 M
Slightly volatile
Other Operating Expenses581.9 M554.2 M153.1 M
Slightly volatile
Research Development459.3 M437.4 M122.3 M
Slightly volatile
Cost Of Revenue459.3 M437.4 M69.7 M
Slightly volatile
Total Operating Expenses581.9 M554.2 M153.1 M
Slightly volatile
Interest Income1.5 M2.9 M1.1 M
Slightly volatile
Reconciled Depreciation19.5 M18.6 M4.9 M
Slightly volatile
Non Operating Income Net Other17.5 M19.6 M21.4 M
Slightly volatile
Selling And Marketing Expenses16 M18 M19.6 M
Slightly volatile

Beam Therapeutics Cash Flow Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Stock Based Compensation103.6 M98.6 M24.1 M
Slightly volatile
Other Cashflows From Financing Activities8.1 M8.5 M19 M
Very volatile
Depreciation21 M20 M4.8 M
Slightly volatile
Capital Expenditures27 M33.7 M13.4 M
Slightly volatile
Total Cash From Financing Activities266 M276.4 M132.9 M
Slightly volatile
End Period Cash Flow256.4 M435.9 M126.8 M
Slightly volatile
Begin Period Cash Flow216.9 M232.8 M94.4 M
Slightly volatile
Issuance Of Capital Stock306.4 M268.5 M227.7 M
Slightly volatile
Change To Netincome18.5 M19.5 M73.4 M
Slightly volatile
Dividends Paid10.2 M11.4 M12.5 M
Slightly volatile
Cash And Cash Equivalents Changes316.6 M356.2 M387.8 M
Slightly volatile
Cash Flows Other Operating41.5 M46.7 M50.8 M
Slightly volatile
Other Cashflows From Investing Activities496 K558 K607.6 K
Slightly volatile

Financial Ratios

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio5.285.5646.3 K
Slightly volatile
Dividend Yield0.01060.01190.0129
Slightly volatile
Days Sales Outstanding1.7 K1.9 K2.1 K
Slightly volatile
Stock Based Compensation To Revenue0.250.2612303
Slightly volatile
Capex To Depreciation1.61.685619.4589
Slightly volatile
EV To Sales4.624.864545.7 K
Slightly volatile
Payables Turnover28427038.4293
Slightly volatile
Sales General And Administrative To Revenue0.290.3093844
Slightly volatile
Research And Ddevelopement To Revenue1.11.1582.3 K
Slightly volatile
Capex To Revenue0.08480.0893509
Slightly volatile
Cash Per Share16.1915.42255.4603
Slightly volatile
Days Payables Outstanding1.281.34942.5 K
Slightly volatile
Net Debt To EBITDA0.911.6790.6426
Slightly volatile
Current Ratio3.165.89132.1999
Slightly volatile
Receivables Turnover0.140.160.1698
Slightly volatile
Graham Number16.4322.17211.6696
Slightly volatile
Capex Per Share0.330.43720.2251
Slightly volatile
Revenue Per Share5.144.89570.7811
Slightly volatile
Interest Debt Per Share0.0060.00630.0638
Pretty Stable
Debt To Assets3.0E-43.0E-40.2248
Slightly volatile
Days Of Payables Outstanding1.281.34942.5 K
Slightly volatile
Ebt Per Ebit1.340.74321.132
Very volatile
Quick Ratio3.495.89132.4116
Slightly volatile
Net Income Per E B T1.141.01041.0193
Slightly volatile
Cash Ratio2.612.12051.4132
Slightly volatile
Days Of Sales Outstanding1.7 K1.9 K2.1 K
Slightly volatile
Fixed Asset Turnover1.671.58830.2533
Slightly volatile
Debt Ratio3.0E-43.0E-40.2248
Slightly volatile
Price Sales Ratio5.285.5646.3 K
Slightly volatile
Asset Turnover0.270.25880.0407
Slightly volatile

Beam Therapeutics Valuation Data

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Market Cap3.8 B2.1 B3.7 B
Pretty Stable
Enterprise Value3.5 B1.8 B3.6 B
Slightly volatile

Beam Fundamental Market Drivers

Cash And Short Term Investments1.2 B

Beam Upcoming Events

27th of February 2024
Upcoming Quarterly Report
View
8th of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
27th of February 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About Beam Therapeutics Financial Statements

Beam Therapeutics investors utilize fundamental indicators, such as revenue or net income, to predict how Beam Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
Last ReportedProjected for Next Year
Current Deferred Revenue68.7 M57 M
Cost Of Revenue437.4 M459.3 M
Total Revenue377.7 M396.6 M
Stock Based Compensation To Revenue 0.26  0.25 
Sales General And Administrative To Revenue 0.31  0.29 
Research And Ddevelopement To Revenue 1.16  1.10 
Capex To Revenue 0.09  0.08 
Revenue Per Share 4.90  5.14 
Ebit Per Revenue(0.47)(0.49)

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect
When determining whether Beam Therapeutics is a strong investment it is important to analyze Beam Therapeutics' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Beam Therapeutics' future performance. For an informed investment choice regarding Beam Stock, refer to the following important reports:
How To Invest In Beam
Details
Is Beam Stock a good investment?
Details
What is Beam Therapeutics' Net Worth?
Details
Largest Biotechnology Companies
View
Largest Pharmaceuticals, Biotechnology & Life Sciences Companies
View
Check out the analysis of Beam Therapeutics Correlation against competitors.
To learn how to invest in Beam Stock, please use our How to Invest in Beam Therapeutics guide.
You can also try the Sync Your Broker module to sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors..
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Beam Therapeutics. If investors know Beam will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Beam Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(1.58)
Revenue Per Share
4.273
Quarterly Revenue Growth
(0.17)
Return On Assets
(0.09)
Return On Equity
(0.18)
The market value of Beam Therapeutics is measured differently than its book value, which is the value of Beam that is recorded on the company's balance sheet. Investors also form their own opinion of Beam Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Beam Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Beam Therapeutics' market value can be influenced by many factors that don't directly affect Beam Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Altman
Z Score
Details
Piotroski
F Score
Details
Beneish
M Score
Details
Financial
Analysis
Details
Buy or Sell
Advice
Details
Earnings
Projections
Details
Please note, there is a significant difference between Beam Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Beam Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Beam Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2024 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY